Authors
Cilin Zhao, Xiaolan Luo, Yajuan Fu, Huixia Yang, Jiaqi Yang, Feifei Yu, Xiaoyan Dong, Huiping Zhang, Yinju Hao, Bin Liu, Yideng Jiang
Published in
Journal of nanobiotechnology. Jul 13, 2026. Epub Jul 13, 2026.
Abstract
The progression of atherosclerosis (AS) is closely related to endothelial senescence and abnormal lipid metabolism in macrophages. Although metformin (Met) can exert vascular endothelial protective effects by inhibiting endothelial cell senescence, the drug exhibits limited capacity to regulate lipid metabolism. In contrast, evolocumab (Evol), a PCSK9-specific inhibitor, can lower LDL-C levels to reduce foam cell formation. This study takes pathological endothelial cells and macrophages as core targets. Leveraging the complementary between Met-mediated anti-endothelial senescence and Evol-regulated lipid metabolism, S2P peptide-modified PLGA nanocarriers (S-P@(Met + Evol) NPs) were constructed to achieve co-delivery of the two drugs, further enhancing the dual-targeting function of the nanomedicine. In vitro studies showed that S-P@(Met + Evol) NPs effectively reduced oxidative damage, inhibited vascular aging and enhanced macrophage cholesterol efflux. In vivo studies showed that this nanodrug significantly alleviated aging damage, lipid accumulation, and inflammatory responses, synergistically reduced plaque burden, enhanced plaque stability, and exhibited a good safety profile. In conclusion, this dual-cell targeted synergistic regulation strategy provides an effective approach for the treatment of AS.
PMID:
42443909
Bibliographic data and abstract were imported from PubMed on 14 Jul 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 3
- Comments 0